What Does The Future Hold For Aadi Bioscience, Inc. (NASDAQ:AADI)? These Analysts Have Been Cutting Their Estimates
What Does The Future Hold For Aadi Bioscience, Inc. (NASDAQ:AADI)? These Analysts Have Been Cutting Their Estimates
The latest analyst coverage could presage a bad day for Aadi Bioscience, Inc. (NASDAQ:AADI), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. At US$4.71, shares are up 4.7% in the past 7 days. It will be interesting to see if this downgrade motivates investors to start selling their holdings.
最新的分析师报道可能预示着Aadi Bioscience, Inc.(纳斯达克股票代码:AADI)将迎来糟糕的一天,分析师全面下调了法定估计,这可能会让股东有些震惊。该报告侧重于收入估计,看来该业务的共识观点已变得更加保守。股价为4.71美元,在过去7天内上涨4.7%。看看降级是否会激励投资者开始出售所持股份将很有趣。
After this downgrade, Aadi Bioscience's four analysts are now forecasting revenues of US$27m in 2024. This would be a meaningful 17% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$33m in 2024. It looks like forecasts have become a fair bit less optimistic on Aadi Bioscience, given the substantial drop in revenue estimates.
在此次降级之后,Aadi Bioscience的四位分析师现在预测2024年的收入为2700万美元。与过去12个月相比,这将使销售额大幅增长17%。在最新估计之前,分析师预测2024年的收入为3,300万美元。鉴于收入预期大幅下降,看来对Aadi Bioscience的预测已经不那么乐观了。
See our latest analysis for Aadi Bioscience
查看我们对Aadi Bioscience的最新分析
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231116/0-79ec80094550937237a07f493603ff84-0-ee5165d90f80932244d3ad88d5c6fa20.png/big)
The consensus price target fell 6.4% to US$33.00, with the analysts clearly less optimistic about Aadi Bioscience's valuation following this update.
共识目标股价下跌6.4%,至33.00美元,在此更新之后,分析师对Aadi Bioscience的估值显然不那么乐观。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Aadi Bioscience's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 13% growth on an annualised basis. This is compared to a historical growth rate of 24% over the past three years. Compare this to the 669 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 16% per year. So it's pretty clear that, while Aadi Bioscience's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
获取有关这些预测的更多背景信息的一种方法是研究它们与过去的业绩相比如何,以及同一行业中其他公司的表现。很明显,预计Aadi Bioscience的收入增长将大幅放缓,到2024年底,收入预计将按年计算增长13%。相比之下,过去三年的历史增长率为24%。相比之下,该行业其他669家拥有分析师资格的公司,预计这些公司的收入将以每年16%的速度增长。因此,很明显,尽管Aadi Bioscience的收入增长预计将放缓,但预计其增长将与行业大致持平。
The Bottom Line
底线
The clear low-light was that analysts slashing their revenue forecasts for Aadi Bioscience next year. They're also forecasting for revenues to grow at about the same rate as companies in the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of Aadi Bioscience's future valuation. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Aadi Bioscience after today.
明显的弱点是,分析师下调了对Aadi Bioscience明年的收入预期。他们还预测,收入的增长速度将与整个市场中的公司大致相同。共识目标股价大幅下跌,分析师似乎对最近的业务发展感到放心,这导致对Aadi Bioscience未来估值的估计降低。通常,一次降级可能会引发一连串的削减,尤其是在行业衰退的情况下。因此,如果今天之后市场对Aadi Bioscience变得更加谨慎,我们也不会感到惊讶。
Hungry for more information? We have estimates for Aadi Bioscience from its four analysts out until 2025, and you can see them free on our platform here.
想了解更多信息吗?我们有四位分析师对Aadi Bioscience的估计,直到2025年,你可以在我们的平台上免费看到这些估计。
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
寻找可能达到转折点的有趣公司的另一种方法是使用内部人士收购的成长型公司的免费清单,跟踪管理层是买入还是卖出。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。